HealthdirectFree Australian health advice you can count on.

( ARTG ) Metastatic breast cancer,HER2-positive,ENHERTU as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who previously received:, trastuzumab and a taxane for metastatic disease, or, one prior anti-HER2-based regimen and developed disease recurrence during or within six months of completing neo-adjuvant or adjuvant therapy.,HER2-low,ENHERTU as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-negative) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.‍​‍‍‍​‍‍‍‍‍‍‍‍​‍ Patients with hormone receptor positive (HR+) breast cancer should additionally have received and no longer be considered eligible for endocrine therapy.,HER2-low and HER2-ultralow,ENHERTU as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HR+ and either HER2-low (IHC 1+ or IHC 2+/ISH-negative) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.Locally advanced or metastatic gastric cancer,ENHERTU is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen. This indication was approved via the provisional approval pathway based on objective response rate. Continued approval of this indication depends on verification and description of benefit in a confirmatory trial.,Other unresectable or metastatic solid tumours,ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2- positive (IHC3+) solid tumours who have received prior systemic treatment and who have no satisfactory alternative treatment options. This indication was approved via the provisional approval pathway based on objective response rate. Full registration of this indication depends on submission of further clinical data to confirm the clinical benefit of the medicine.,Unresectable or metastatic non-small cell lung cancer (NSCLC),ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic NSCLC whose tumours have activating HER2 (ERBB2) mutations and who have received prior platinumbased chemotherapy with or without immunotherapy. This indication was approved via the provisional approval pathway based on objective response rate. Continued approval of this indication depends on verification and description of benefit in a confirmatory trial.